adavosertib + durvalumab

Adavosertib + durvalumab is a combination of two investigational drugs for cancer therapy. **Adavosertib** (AZD1775) is an orally administered, first-in-class, selective small molecule inhibitor of Wee1 kinase, which disrupts the G2/M checkpoint in tumor cells, leading to cell cycle arrest and apoptosis, particularly in p53-deficient tumors. **Durvalumab** (MEDI4736) is a monoclonal antibody that inhibits the programmed death ligand 1 (**PD-L1**), blocking its interaction with PD-1 and CD80 receptors, and thereby promoting an immune-mediated anti-tumor response. The combination aims to increase anti-tumor efficacy by simultaneously targeting tumor cell division and enhancing immune activity. This drug combination has been evaluated in phase 1 clinical trials for advanced solid tumors, focusing on safety, tolerability, and dose determination[1][2].

Brand names

Durvalumab

Other names

adavosertib + durvalumabAZD1775 + MEDI4736